Her2 low status and response to neoadjuvant chemotherapy in Her2 negative early breast cancer

被引：0
|
作者：
Mattos, Bruna RaphaeliSilva [1 ]
Cesca, Marcelle Goldner [1 ]
Leite, Luciana de Moura [1 ]
Tavares, Monique Celeste [1 ]
Silva, Sinara Figueiredo [1 ]
Pirolli, Rafaela [1 ]
Fogassa, Camilla AlbinaZanco [1 ]
Silva, Erick Figueiredo [1 ]
Rocha, Francisca Giselle [1 ]
Loose, Simone Klug [1 ]
Campos, Fernando AugustoBatista [1 ]
Sanches, Solange Moraes [1 ]
de Lima, Vladmir ClaudioCordeiro [1 ]
Ponde, Noam Falbel [1 ]
机构：
[1] AC Camargo Canc Ctr, Sao Paulo, Brazil
来源：
CANCER RESEARCH | 2021年 / 81卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
PS4-40
引用
收藏
页数：2
相关论文
共 50 条
  • [31] HER2 Immunohistochemistry Positivity is Strongly Predictive of HER2 Positive Breast Cancer Response to Neoadjuvant Therapy
    Zhao, Jing
    Zhang, Chao
    Suo, Aili
    Shi, Qiuying
    Wei, Zhimin
    Li, Zaibo
    Krishnamurti, Uma
    Li, Xiaoxian
    LABORATORY INVESTIGATION, 2019, 99
  • [32] Hormone receptor and HER2 status: The only predictive factors of response to neoadjuvant chemotherapy in breast cancer
    Baulies, S.
    Cusido, M.
    Gonzalez-Cao, M.
    Tresserra, F.
    Fargas, F.
    Rodriguez, I.
    Ubeda, B.
    Ara, C.
    Fabregas, R.
    JOURNAL OF OBSTETRICS AND GYNAECOLOGY, 2015, 35 (05) : 485 - 489
  • [33] HER2 Gene Protein Assay Is Useful to Determine HER2 Status and Evaluate HER2 Heterogeneity in HER2 Equivocal Breast Cancer
    Hou, Yanjun
    Nitta, Hiroaki
    Li, Zaibo
    AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 2017, 147 (01) : 89 - 95
  • [34] Evaluation of analytical accuracy of HER2 status in patients with breast cancer Comparison of HER2 GPA with HER2 IHC and HER2 FISH
    Jensen, Steffen Grann
    Thomas, Peter Engel
    Christensen, Ib Jarle
    Balslev, Eva
    Hansen, Alastair
    Hogdall, Estrid
    APMIS, 2020, 128 (11) : 573 - 582
  • [35] Impact of neoadjuvant HER2-directed therapy on HER2 status in breast cancer
    Manguso, Nicholas
    Johnson, Jeffrey
    Basho, Reva Kakkar
    McArthur, Heather L.
    Tanaka, Hisashi
    Giuliano, Armando E.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [36] Alterations in HER2 status and outcome following neoadjuvant chemotherapy in HER2-positive breast cancer (BC)
    Ng, Dianna
    Krings, Gregor
    Yau, Christina
    White, Kristie
    Hou, Jie
    Chua, Anthony
    Grenert, James P.
    Chen, Yunn-Yi
    CANCER RESEARCH, 2015, 75
  • [37] Activating HER2 Mutations in HER2 Gene Amplification Negative Breast Cancer
    Bose, Ron
    Kavuri, Shyam M.
    Searleman, Adam C.
    Shen, Wei
    Shen, Dong
    Koboldt, Daniel C.
    Monsey, John
    Goel, Nicholas
    Aronson, Adam B.
    Li, Shunqiang
    Ma, Cynthia X.
    Ding, Li
    Mardis, Elaine R.
    Ellis, Matthew J.
    CANCER DISCOVERY, 2013, 3 (02) : 224 - 237
  • [38] HEr2 testing in neoadjuvant breast cancer trials - improved concordance of HER2 status in different pathology laboratories
    Pfitzner, B.
    Lederer, B.
    Lindner, J.
    Solbach, C.
    Engels, K.
    Rezai, M.
    Dohnal, K.
    Tesch, H.
    Hansmann, M. -L.
    Salat, C.
    Beer, M.
    Schneeweiss, A.
    Sinn, P.
    von Minckwitz, G.
    Denkert, C.
    Loibl, S.
    ONCOLOGY RESEARCH AND TREATMENT, 2016, 39 : 56 - 56
  • [39] Neoadjuvant therapy in patients with triple negative and HER2 positive early breast cancer
    Harbeck, N.
    BREAST, 2017, 32 : S18 - S18
  • [40] Loss of HER2 after neoadjuvant treatment of HER2+early breast cancer
    Morales, S.
    Gasol Cudos, A.
    Rodriguez Galindo, A.
    Velasco, A.
    Canosa Morales, C.
    Sanchez Guzman, D. -R.
    Mele Olive, J.
    ANNALS OF ONCOLOGY, 2020, 31 : S51 - S51
12345